February 26, 2021
Data published in The Lancet Oncology investigating patients with malignant pleural mesothelioma determined that surgery for mesothelioma after radiotherapy, or SMART, can produce positive early- and long-term effects.
February 25, 2021
Data published in The Lancet Oncology found that a hypofractionated radiation schedule of 55 Gy in 20 fractions is noninferior to a schedule of 64 Gy in 32 fractions for patients with this disease.
February 25, 2021
Data examining 4 low-value breast cancer procedures found an association between facility-level characteristics and the use of these procedures, suggesting a need for de-implementation targeting efforts in various facilities.
February 24, 2021
The PHERGain II trial will investigate the treatment of patients with early HER2-positive breast cancer using a chemotherapy-free treatment approach of trastuzumab plus pertuzumab.
February 24, 2021
A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.
February 23, 2021
Richard Schilsky, MD, touched on the research driving ASCO to award “Advance of the Year” to molecular profiling in gastrointestinal cancers, and what the organization’s top priorities are in the near future.
February 22, 2021
Celsion Corporation announced that fast track designation was granted to their immunotherapy, GEN-1, to treat patients with advanced stage III or IV ovarian cancer.
February 22, 2021
Follow-up data published in the European Association of Urology did not find a significant improvement in overall survival for patients with locally advanced renal cell carcinoma undergoing adjuvant pazopanib treatment.
February 19, 2021
Data published in Patient Preference and Adherence found communication improved between patients with CLL and their oncologists when the risk of adverse events and patient goals were top of mind.
February 18, 2021
A retrospective, population-based cohort study in JAMA Oncology found Black women in the United States were more likely to have a high-risk recurrence score and die of axillary node-negative breast cancer than non-Hispanic White women who had similar scores.